Xiangxue PharmaceuticalLtd Yönetim

Yönetim kriter kontrolleri 3/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Yonghui Wang

İcra Kurulu Başkanı

CN¥900.0k

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	14.3yrs
CEO sahipliği	n/a
Yönetim ortalama görev süresi	2.4yrs
Yönetim Kurulu ortalama görev süresi	5.4yrs

Son yönetim güncellemeleri

Recent updates

CEO

Yonghui Wang (62 yo)

14.3yrs

Görev süresi

CN¥900,000

Tazminat

Mr. Yonghui Wang serves as General Manager and Chairman of Xiangxue Pharmaceutical Co., Ltd. since July 23, 2010. Mr. Wang served as Deputy General Manager of Guangzhou Wanbao Group Industrial Washing Mach...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Yonghui Wang	Chairman & GM	14.3yrs	CN¥900.00k	Veri yok
Xiaoyan Niu	Financial Director	2.4yrs	CN¥360.00k	0.0023% CN¥ 189.4k
Li Xu	Secretary of the Board of Directors & Non-Independent Director	no data	CN¥240.00k	0.030% CN¥ 2.5m
Lun Zeng	Vice President	no data	CN¥960.00k	0.060% CN¥ 5.0m
Guanghua Tan	General Manager of Marketing Center	2.4yrs	CN¥530.00k	0.039% CN¥ 3.3m
Zhiying Kang	GM of Technology R&D	no data	CN¥240.00k	0.046% CN¥ 3.9m
Feng Lu	Director of Internal Audit	2.4yrs	CN¥180.00k	0.037% CN¥ 3.1m
Junliang Zhong	Supply Chain General Manager	2.4yrs	CN¥263.00k	Veri yok

2.4yrs

Ortalama Görev Süresi

49yo

Ortalama Yaş

Deneyimli Yönetim: 300147 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2.4 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Yonghui Wang	Chairman & GM	14.3yrs	CN¥900.00k	Veri yok
Li Xu	Secretary of the Board of Directors & Non-Independent Director	5.4yrs	CN¥240.00k	0.030% CN¥ 2.5m
Wen Jin Chen	Director	2.3yrs	CN¥240.00k	0.0091% CN¥ 756.9k
Zi Yu Mo	Non-Employee Representative Supervisor	8.5yrs	CN¥320.00k	0.027% CN¥ 2.3m
Wen Hui Tan	Non-Independent Director	14.3yrs	Veri yok	0.020% CN¥ 1.7m
Jun Hui Chen	Non-Employee Representative Supervisor	8.5yrs	Veri yok	Veri yok
Qingquan Zhou	Independent Director	5.4yrs	CN¥60.00k	Veri yok
Jianhong Tao	Independent Director	3.3yrs	CN¥60.00k	Veri yok
Jie Wu	Independent Director	3.3yrs	CN¥60.00k	Veri yok
Wei Hua Huang	Chairman of the Supervisory Board	5.4yrs	CN¥280.00k	0.028% CN¥ 2.4m

5.4yrs

Ortalama Görev Süresi

57yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 300147 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 5.4 yıldır).

Xiangxue PharmaceuticalLtd Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

Xiangxue Pharmaceutical Co.,Ltd., Annual General Meeting, Jun 07, 2024

Xiangxue Pharmaceutical Co.,Ltd., Annual General Meeting, Jun 30, 2023

Insufficient new directors

Xiangxue Pharmaceutical Co.,Ltd. Approves Board Elections

Xiangxue Pharmaceutical Co.,Ltd., Annual General Meeting, Jun 24, 2022

Recent updates

New major risk - Financial position

Xiangxue Pharmaceutical Co.,Ltd. to Report Q3, 2024 Results on Oct 26, 2024

Second quarter 2024 earnings released: CN¥0.16 loss per share (vs CN¥0.081 loss in 2Q 2023)

Xiangxue Pharmaceutical Co.,Ltd. to Report First Half, 2024 Results on Aug 29, 2024

Xiangxue Pharmaceutical Co.,Ltd., Annual General Meeting, Jun 07, 2024

Full year 2023 earnings released: CN¥0.59 loss per share (vs CN¥0.81 loss in FY 2022)

Xiangxue Pharmaceutical Co.,Ltd. to Report Q1, 2024 Results on Apr 29, 2024

New minor risk - Share price stability

Xiangxue Pharmaceutical Co.,Ltd. to Report Fiscal Year 2023 Results on Apr 27, 2024

Third quarter 2023 earnings released: CN¥0.12 loss per share (vs CN¥0.19 loss in 3Q 2022)

Second quarter 2023 earnings released: CN¥0.081 loss per share (vs CN¥0.18 loss in 2Q 2022)

Xiangxue Pharmaceutical Co.,Ltd. announced that it expects to receive CNY 959.884 million in funding

New major risk - Financial position

Xiangxue Pharmaceutical Co.,Ltd., Annual General Meeting, Jun 30, 2023

Full year 2022 earnings released: CN¥0.81 loss per share (vs CN¥1.04 loss in FY 2021)

Third quarter 2022 earnings released: CN¥0.19 loss per share (vs CN¥0.077 loss in 3Q 2021)

Second quarter 2022 earnings released: CN¥0.18 loss per share (vs CN¥0.04 profit in 2Q 2021)

Insufficient new directors

Xiangxue Pharmaceutical Co.,Ltd. Approves Board Elections

Xiangxue Pharmaceutical Co.,Ltd., Annual General Meeting, Jun 24, 2022

Full year 2021 earnings released: CN¥1.04 loss per share (vs CN¥0.15 profit in FY 2020)

Third quarter 2021 earnings released: CN¥0.077 loss per share (vs CN¥0.01 profit in 3Q 2020)

First quarter 2021 earnings released: EPS CN¥0.04 (vs CN¥0.12 in 1Q 2020)

Xiangxue Pharmaceutical Co.,Ltd. to Report Fiscal Year 2020 Results on Apr 10, 2021

New 90-day low: CN¥8.31

New 90-day low: CN¥8.83

New 90-day low: CN¥9.90

Third quarter earnings released

New 90-day high: CN¥12.89

Market bids up stock over the past week

Xiangxue Pharmaceutical Co.,Ltd. to Report Q3, 2020 Results on Oct 24, 2020

111, Inc. and Guangzhou Xiangxue Pharmaceutical Co., Ltd. Officially Sign Strategic Partnership Agreement

New 90-day high - CN¥11.96

First half earnings released

Xiangxue Pharmaceutical Co.,Ltd. to Report First Half, 2020 Results on Aug 28, 2020

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş